ALLMedicine™ Atrial Flutter Center

Aug 3rd, 2022 - The Acutus Medical AcQForce Flutter clinical study is a prospective, multi-center, non-randomized global study designed to demonstrate the safety and effectiveness of the AcQBlate Force Sensing Ablation System in the ablation management of symptom...

Aug 2nd, 2022 - There is limited data on temporal trends of cardiovascular hospitalizations and outcomes amongst cancer patients. We describe the distribution, trends of admissions, and in-hospital mortality associated with key cardiovascular diseases among cance...

Jul 30th, 2022 - Atrial fibrillation (AF)/atrial flutter is common during cardiac amyloidosis (CA). Electrical cardioversion (EC) is a strategy to restore sinus rhythm (SR). However, left atrial thrombus (LAT) represents a contraindication for EC. CA patients with...

Jul 25th, 2022 - AFLOAT is a national, multicenter, randomized, controlled, open-label superiority study with a blind evaluation of all the endpoints (PROBE design). The interventional phase is followed by an observational phase as long as the patient is implanted...

Jul 22nd, 2022 - Roof-dependent atrial flutter (AFL) is a major tachyarrhythmia rotating in the left atrium (LA). Here, we describe a case of roof-dependent AFL during atrial fibrillation ablation. LA posterior wall (LAPW) debulking ablation was performed before t...

Dec 12th, 2020 - 2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.|2020|Hei...

Feb 19th, 2011 - The stroke rate in atrial fibrillation is 4.5% per year, with death or permanent disability in over half. The risk of stroke varies from under 1% to over 20% per year, related to the risk factors of congestive heart failure, hypertension, age, dia...

Feb 20th, 2008 - ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the...

Aug 3rd, 2022 - The Acutus Medical AcQForce Flutter clinical study is a prospective, multi-center, non-randomized global study designed to demonstrate the safety and effectiveness of the AcQBlate Force Sensing Ablation System in the ablation management of symptom...

Jul 25th, 2022 - AFLOAT is a national, multicenter, randomized, controlled, open-label superiority study with a blind evaluation of all the endpoints (PROBE design). The interventional phase is followed by an observational phase as long as the patient is implanted...

Jul 20th, 2022 - Atrial fibrillation (AF) is a heart rhythm disorder associated with debillitating symptoms, psychological distress and heart failure. It can also significantly increase an individuals stroke risk. Catheter ablation (CA) for AF is the most effectiv...

Jul 19th, 2022 - Atrial flutter is a common condition that is effectively treated by ablation using radiofrequency. Due to its feasibility, effectiveness and low procedural risk, radiofrequency ablation is a first-line treatment of atrial flutter. Several studies ...

Jul 15th, 2022 - Atrial fibrillation and atrial flutter are the most common arrhythmias among the adult population of the world, their share in the population is from 2 to 4% and continues to grow. Modern highly effective methods of minimally invasive surgical tre...

Aug 5th, 2022 - Although cardiovascular disease (CVD) is known to often strike the mortal blow in patients with cancer, a national analysis puts in stark relief the burden of CV-related hospitalizations in this vulnerable population. Results show that between 200...

Jul 7th, 2022 - Over roughly the past decade, there has been rapid development and swift uptake of consumer technology capable of recording physiologic data relevant to cardiac health, including physical activity, heart rate, electrocardiograms, and episodes of a...

Mar 21st, 2022 - Study Overview Objective: To assess the safety and efficacy of early hospital discharge (EHD) for selected low-risk patients with ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI). Design: Si.

Jan 20th, 2022 - William Wierda, MD, PhD: Let’s start with the updates that we’ve had available over the last year. Jackie, we can start with you and if you could sort of give us your thoughts and comments around recent updates over the last data about ibrutinib [...

Jan 3rd, 2022 - Preetesh Jain, MD, PhD, discusses data from the following study: Ibrutinib plus rituximab and venetoclax followed by risk-stratified observation or short-course R-hyper-CVAD [rituximab, cyclophosphamide, vincristine, doxorubicin hydrochloride, de...